Raymond James & Associates’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-7,990
| Closed | -$1.32M | – | 4334 |
|
|
2021
Q2 | $1.32M | Sell |
7,990
-293
| -4% | -$48.9K | ﹤0.01% | 2399 |
|
|
2021
Q1 | $1.27M | Sell |
8,283
-455
| -5% | -$61.8K | ﹤0.01% | 2337 |
|
|
2020
Q4 | $1.1M | Sell |
8,738
-86
| -1% | -$9.62K | ﹤0.01% | 2283 |
|
|
2020
Q3 | $895K | Buy |
8,824
+721
| +9% | +$73.5K | ﹤0.01% | 2243 |
|
|
2020
Q2 | $788K | Sell |
8,103
-4,201
| -34% | -$391K | ﹤0.01% | 2319 |
|
|
2020
Q1 | $1.02M | Buy |
12,304
+1,014
| +9% | +$98.9K | ﹤0.01% | 1962 |
|
|
2019
Q4 | $1.25M | Sell |
11,290
-194
| -2% | -$20K | ﹤0.01% | 2134 |
|
|
2019
Q3 | $1.14M | Sell |
11,484
-295
| -3% | -$29.3K | ﹤0.01% | 2123 |
|
|
2019
Q2 | $1.17M | Sell |
11,779
-19,500
| -62% | -$1.86M | ﹤0.01% | 2124 |
|
|
2019
Q1 | $3.45M | Sell |
31,279
-7,365
| -19% | -$770K | 0.01% | 1412 |
|
|
2018
Q4 | $3.55M | Buy |
38,644
+6,058
| +19% | +$613K | 0.01% | 1280 |
|
|
2018
Q3 | $3.59M | Buy |
32,586
+8,861
| +37% | +$923K | 0.01% | 1429 |
|
|
2018
Q2 | $2.21M | Sell |
23,725
-11,555
| -33% | -$995K | ﹤0.01% | 1696 |
|
|
2018
Q1 | $2.93M | Buy |
35,280
+13,962
| +65% | +$1.24M | 0.01% | 1457 |
|
|
2017
Q4 | $1.94M | Buy |
21,318
+7,684
| +56% | +$639K | ﹤0.01% | 1711 |
|
|
2017
Q3 | $1.04M | Sell |
13,634
-345
| -2% | -$26.1K | ﹤0.01% | 2071 |
|
|
2017
Q2 | $1.05M | Buy |
13,979
+4,113
| +42% | +$285K | ﹤0.01% | 1997 |
|
|
2017
Q1 | $644K | Sell |
9,866
-1,992
| -17% | -$117K | ﹤0.01% | 2234 |
|
|
2016
Q4 | $654K | Buy |
11,858
+2,325
| +24% | +$128K | ﹤0.01% | 2167 |
|
|
2016
Q3 | $539K | Buy |
9,533
+3,470
| +57% | +$170K | ﹤0.01% | 2231 |
|
|
2016
Q2 | $253K | Buy |
6,063
+9
| +0.1% | +$415 | ﹤0.01% | 2512 |
|
|
2016
Q1 | $259K | Buy |
+6,054
| New | +$256K | ﹤0.01% | 2429 |
|
Other funds holding PRAH
Raymond James & Associates's PRAH Position: Q3 2021 in Review
Raymond James & Associates sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 7,990 shares — an estimated $1.32M sold.
Raymond James & Associates first reported a position in PRAH in Q1 2016 and held it in 22 quarters. The position peaked at $3.59M in Q3 2018. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Raymond James & Associates reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Raymond James & Associates sold 7,990 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $1.32M.
- Raymond James & Associates first reported a position in PRA Health Sciences, Inc. in Q1 2016 and held it in 22 quarters.
- Raymond James & Associates's PRA Health Sciences, Inc. position peaked at $3.59M in Q3 2018.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.